Approximately 9 million nuclear cardiology studies performed each year in the United States employ technetium-99m, which is produced from the decay of molybdenum-99. The fragility of the worldwide technetium-99m supply chain has been underscored by current shortages caused by an unplanned shutdown of Europe’s largest reactor. The majority of the United States’ supply derives from a reactor in Canada nearing the end of its lifespan, whose planned replacements have been recently cancelled. In this article, the clinical importance of technetium-99m and our tenuous dependence on foreign supply of Molybdenum is addressed.
展开▼
